| Features: |
| Psoralidin is a prenylated coumestan isolated primarily from Psoralea corylifolia (Babchi). It is not a classical anticancer drug. Psoralidin generally acts to suppress oncogenic signaling and survival pathways while promoting apoptosis in tumor cells. Reported effects (context-dependent, preclinical): -DOWNREGULATES pro-survival pathways (e.g., NF-κB, STAT3) -UPREGULATES apoptotic signaling (caspase activation) -MODULATES androgen receptor signaling in prostate cancer models -SENSITIZES tumor cells to chemo- and radio-induced stress This positions psoralidin as a biologic modulator, not a driver. Across cancer cell and animal models, psoralidin has been associated with: -Apoptosis induction -Caspase activation -Mitochondrial depolarization -Inflammatory pathway suppression -NF-κB inhibition -STAT3 attenuation -Hormone signaling modulation -Androgen receptor suppression (prostate cancer context) -Oxidative stress interaction -Redox imbalance tipping tumor cells toward death under stress Psoralidin is best described as chemopreventive or chemo-sensitizing, not chemoprotective |
| Source: |
| Type: |
| The term "IL-1" is often used as an umbrella term for the interleukin-1 family, which includes multiple cytokines. The two best-known members are IL-1α and IL-1β. IL-1β is secreted from cells and plays a major systemic role in inflammation. It is a crucial mediator in the inflammatory response and is involved in the fever response, activation of endothelial cells, and leukocyte recruitment. Its increased expression is commonly linked to: – Promotion of a pro-inflammatory microenvironment that supports tumor growth. – Enhanced angiogenesis, invasion, and metastasis. – Recruitment of myeloid cells that may further suppress antitumor immunity. High expression of either tends to be associated with a more aggressive phenotype and worse prognosis in many cancer types. |
| 4966- | PSO, | Psoralidin induces pyroptosis in both tumor cells and macrophages as well as enhances nature killer cell cytotoxicity to suppress hepatocellular carcinoma |
| - | vitro+vivo, | HCC, | HepG2 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:389 Target#:978 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid